Table 2.
Analysis of factors associated with successful outcome using univariate logistic regression analysis (n = 207)
| Factors | Failure of 131I Treatment | Successful 131I Treatment | p-value |
|---|---|---|---|
| N = 42 (%) | N = 165 (%) | ||
| Gender | |||
| Male | 21 (50%) | 57 (34.54%) | 0.076 |
| Female | 21 (50%) | 108 (65.45%) | |
| Family history of thyrotoxicosis | |||
| Negative | 37 (88.1%) | 140 (84.85%) | 0.806 |
| Positive | 5 (11.9%) | 25 (15.15%) | |
| History of medical treatment | |||
| Negative | 0 (0.0%) | 9 (5.45%) | 0.209 |
| Positive | 42 (100%) | 156 (94.54%) | |
| History of surgery | |||
| Negative | 41 (97.62%) | 126 (76.36%) | 0.001 |
| Positive | 1 (2.38%) | 39 (23.64%) | |
| GO* | |||
| Absent | 39 (92.86%) | 153 (92.73%) | 0.977 |
| Present | 3 (7.14%) | 12 (7.27%) | |
| Patient age (mean ± SD) | 38.36 ± 13.37 | 38.90 ± 11.66 | 0.795 |
| Baseline TSH (mean ± SD) | 0.036 ± 0.061 | 0.027 ± 0.038 | 0.241 |
| Baseline FT3 (mean ± SD) | 13.28 ± 12.84 | 10.63 ± 10.58 | 0.167 |
| Baseline FT4 (mean ± SD) | 7.90 ± 5.94 | 8.64 ± 6.19 | 0.490 |
| Baseline thyroid uptake (mean ± SD) | 21.33 ± 12.57 | 17.72 ± 11.16 | 0.070 |
| 131I dose in (mean ± SD) | 434.4 ± 99.9 MBq (11.74 ± 2.7 mCi) | 502.8 ± 136.9 MBq (13.59 ± 3.7 mCi) | 0.003 |
*
GO: Graves’ ophthalmopathy.